These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Gajewski TF Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753 [TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy of melanoma]. Dréno B Bull Acad Natl Med; 2010 Oct; 194(7):1373-81. PubMed ID: 22043632 [TBL] [Abstract][Full Text] [Related]
17. [Possibilities of immunotherapy in malignant melanoma]. Lewis MG Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650 [TBL] [Abstract][Full Text] [Related]
18. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Jack A; Boyes C; Aydin N; Alam K; Wallack M Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006 [TBL] [Abstract][Full Text] [Related]
19. Melanoma-induced immunosuppression and its neutralization. Umansky V; Sevko A Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515 [TBL] [Abstract][Full Text] [Related]
20. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]